12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Soluble Ferric Pyrophosphate: Phase III ongoing

Rockwell said an independent DSMB for the fourth and final time recommended continuation of the double-blind, placebo-controlled Phase III CRUISE-1 & CRUISE-2 trials of SFP. The trials, which completed enrollment, are evaluating 11 µg/dL...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >